Kala Pharmaceuticals Inc (OQ:KALA)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 490 ARSENAL WAY, SUITE 120
Tel: 1-212-3621200
Website: kalarx.com
IR: See website
Key People
Mark T. Iwicki
Chairman of the Board, President, Chief Executive Officer
Mary Reumuth
Chief Financial Officer, Treasurer
Todd M. Bazemore
Chief Operating Officer
Hongming Chen
Chief Scientific Officer
Eric L. Trachtenberg
Chief Compliance Officer, General Counsel, Secretary
Kim Brazzell
Chief Medical Officer
Business Overview
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company's initial focus is on the treatment of eye diseases. The Company's product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company's product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
Financial Overview
For the three months ended 31 March 2020, Kala Pharmaceuticals Inc revenues decreased 23% to $1.1M. Net loss decreased 14% to $22M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative - Balancing v decrease of 17% to $13.7M (expense), Research and development - Balancing v decrease of 26% to $4.7M (expense).
Employees: 136 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $461.67M as of Mar 31, 2020
Annual revenue (TTM): $5.76M as of Mar 31, 2020
EBITDA (TTM): -$83.40M as of Mar 31, 2020
Net annual income (TTM): -$90.91M as of Mar 31, 2020
Free cash flow (TTM): -$82.61M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 55,715,876 as of Apr 27, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization